Android app Apple app link

Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab

By Yahoo! Finance   |   1 month ago
Summit Therapeutics (SMMT) Expands its Phase 3 Trials for Ivonescimab

Summit Therapeutics Inc. is expanding its Phase 3 clinical program for Ivonescimab, a novel biospecific antibody for colorectal cancer. The company aims to enroll 600 patients globally in trials comparing Ivonescimab with chemotherapy against current treatments.

Read More

Did you find this insightful?

Exclusive Content

Access to this content is reserved for premium members. Unlock all features by upgrading to a premium membership.

Get the App

To join as a premium member, please download our app and complete your membership purchase there.